NASDAQ:ZEAL

Zealand Pharma A/S Stock Forecast, Price & News

$32.58

+0.54 (+1.69 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$32.02

▼

$32.96

50-Day Range

$28.30

▼

$33.46

52-Week Range

$27.90

▼

$44.42

Volume2,160 shs

Average Volume10,760 shs

Market Capitalization$1.42 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.18

30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $29.46
June 2, 2021 | americanbankingnews.com

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
June 2, 2021 | finance.yahoo.com

Total number of shares and voting rights in Zealand Pharma at May 31, 2021
May 31, 2021 | finance.yahoo.com

Zealand Pharma AS (ZEAL) Moves 8.3% Higher: Will This Strength Last?
May 19, 2021 | finance.yahoo.com

Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection
May 12, 2021 | finance.yahoo.com

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes
May 3, 2021 | finance.yahoo.com

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
April 13, 2021 | finance.yahoo.com

With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?
April 12, 2021 | finance.yahoo.com

Scandinavian Tobacco Group A/S: Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities
April 8, 2021 | finanznachrichten.de

The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
March 27, 2021 | feeds.benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
Previous Symbol
CUSIPN/A
CIK1674988
Webwww.zealandpharma.com
Phone45-8877-3600
Employees329
Year FoundedN/A

Sales & Book Value

Annual Sales$54.13 million
Price / Sales26.15
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.73 per share
Price / Book6.89

Profitability

EPS (Most Recent Fiscal Year)($3.38)
Net Income$-129,720,000.00
Net Margins-243.60%
Return on Equity-59.47%
Return on Assets-45.20%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares43,450,000
Market Cap$1.42 billion
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.33 out of 5 stars

Medical Sector

832nd out of 2,100 stocks

Pharmaceutical Preparations Industry

406th out of 832 stocks

3.5 Analyst's Opinion

Consensus Rating
Zealand Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.00, Zealand Pharma A/S has a forecasted upside of 32.0% from its current price of $32.58.
Amount of Analyst Coverage
Zealand Pharma A/S has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
Zealand Pharma A/S has received 286 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zealand Pharma A/S has received 296 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zealand Pharma A/S has received 50.86% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zealand Pharma A/S and other stocks. Vote “Outperform” if you believe ZEAL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zealand Pharma A/S does not currently pay a dividend.
Dividend Growth
Zealand Pharma A/S does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 3.45% of the stock of Zealand Pharma A/S is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Zealand Pharma A/S are expected to grow in the coming year, from ($4.14) to ($3.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zealand Pharma A/S is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zealand Pharma A/S is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zealand Pharma A/S has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

Is Zealand Pharma A/S a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S or view top-rated stocks.

What stocks does MarketBeat like better than Zealand Pharma A/S?

Wall Street analysts have given Zealand Pharma A/S a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zealand Pharma A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Zealand Pharma A/S.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings data on Tuesday, May, 11th. The company reported ($5.78) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.09) by $4.69. Zealand Pharma A/S had a negative net margin of 243.60% and a negative trailing twelve-month return on equity of 59.47%.
View Zealand Pharma A/S's earnings history.

How has Zealand Pharma A/S's stock price been impacted by COVID-19?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZEAL stock has increased by 15.9% and is now trading at $32.58.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ZEAL?

2 brokers have issued 1 year price objectives for Zealand Pharma A/S's stock. Their forecasts range from $42.00 to $44.00. On average, they anticipate Zealand Pharma A/S's share price to reach $43.00 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price.
View analysts' price targets for Zealand Pharma A/S or view top-rated stocks among Wall Street analysts.

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:

Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA, CEO & Pres (Age 52, Pay $2.57M)
Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 46, Pay $522.51k)
Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 68, Pay $64.63k)
Mr. Adam Sinding Steensberg M.D., Exec. VP of R&D and Chief Medical Officer (Age 47, Pay $1.12M)
Mr. Ivan Mourits MÃ¸ller, Sr. VP of Technical Devel. & Operations (Age 49)
Ms. Rie Schultz Hansen, VP of Discovery & Innovation
Lani Pollworth Morvan, Investor Relations & Communications Officer
Mr. Mads Kronborg, Head of Investor Relations & Communication
SÃ¸ren Vitfell Keller, Head of Legal Affairs
Mr. Marino Garcia M.B.A., Sr. VP of Corp. & Bus. Devel. (Age 55)

Who are some of Zealand Pharma A/S's key competitors?

Some companies that are related to Zealand Pharma A/S include TG Therapeutics (TGTX), Schrödinger (SDGR), Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS), Reata Pharmaceuticals (RETA), I-Mab (IMAB), Galapagos (GLPG), Blueprint Medicines (BPMC), Allakos (ALLK), Apellis Pharmaceuticals (APLS), HUTCHMED (HCM), Hypera (HYPMY), ACADIA Pharmaceuticals (ACAD), Sage Therapeutics (SAGE) and Arena Pharmaceuticals (ARNA).
View all of ZEAL's competitors.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Protalix BioTherapeutics (PLX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

Who are Zealand Pharma A/S's major shareholders?

Zealand Pharma A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.09%), Morgan Stanley (0.02%), BlackRock Inc. (0.01%) and UBS Group AG (0.00%).

Which institutional investors are selling Zealand Pharma A/S stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.

Which institutional investors are buying Zealand Pharma A/S stock?

ZEAL stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, BlackRock Inc., and UBS Group AG.

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $32.58.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S has a market capitalization of $1.42 billion and generates $54.13 million in revenue each year. The company earns $-129,720,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis.

How many employees does Zealand Pharma A/S have?

Zealand Pharma A/S employs 329 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

Where are Zealand Pharma A/S's headquarters?

Zealand Pharma A/S is headquartered at SYDMARKEN 11, COPENHAGEN G7, 2860.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here